Dr. Devlin graduated from the Baylor College of Medicine in 1991. He works in Chattanooga, TN and specializes in Neurology. Dr. Devlin is affiliated with Erlanger East Hospital and Erlanger Health System.
This invention relates to the therapeutic uses of oligomers of 15-dehydroprostaglandin B. sub. 1 and oligomers of 16, 16'-dimethyl-15-dehydro PGB. sub. 1 and oligomers or other 16 carbon substituted 15-dehydro PGB. sub. 1 compounds (hereinafter referred to as oligomers of PGB. sub. 1) in tissue ischemia, hyposix and anoxia, (hereinafter referred to collectively as tissue ischemia) and in protecting isolated organs (hearts, kidneys etc. ) and cells (whole blood, erythrocytes, platelets, etc. ) during in vitro transfer and storage; and as a phamacological agent in abnormal conditions in humans and animals in which alteration in cellular calcium is a mediator in the disease process.
Maureen Gilmore, Kevin Smith, Jane Berard, Gail Ciak, Kenneth Racicot, Claire Cournoyer, Richard Bukowski, Francis Ignasiak, Carol Grochowski, Jaucqueta Knight, Pamela Gevry, Lora Gagner